.Attribute Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin led to boosted progression-free and overall survival, resulting in FDA approval as well as a brand new therapy choice for people.